
usd jul pm et
summari rank one world largest pharmaceut compani offer wide rang
price-to-earnings oper ep
past perform indic futur perform reli upon
analysi prepar equiti analyst
may stock trade
target price recent
chang highlight
section stock report updat
invest rationale/risk section
stock report updat shortli
latest news stori marketscop
lower target
ep estim --
histor forward price-to-earnings averag expect
long-term organ revenu growth improv
narrow portfolio patent-protect
drug ep vs beat
consensu maintain
yoy larg driven off-pat drug
segment upjohn revenu saw
post solid growth yoy
constant currenc cc howev driven
cc growth oncolog breast
cancer drug ibranc continu
one strongest perform grow
spin-out upjohn consum
segment expect fast-grow oncolog
portfolio compris total
revenu today think
improv long-term growth remain
neutral share see current
benefit divers portfolio drug
separ brand account annual
sale none contribut total
sale differ brand drug develop
much higher sale concentr howev compani
still subject risk common pharmaceut
compani relat discoveri
develop regulatori clearanc success
commerci new drug well risk
earlier-than-expect gener competit litig
success brand
jul ep estim base cfra oper earn
histor earn report compani report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview one world largest biopharmaceut compani extens
oper drug develop manufactur market compani growth also augment
frequent acquisit largest market approxim sale
gener follow emer market europ
drug portfolio drug portfolio among divers global drug market view
compani top-sel drug prevnar famili vaccin billion sale
total lyrica billion sale total treatment nerv pain epilept seizur
key drug experienc robust growth includ ibranc billion sale
treat breast cancer grew sale eliqui billion stroke embol
grew xeljanz billion treatment arthriti ulcer coliti
grew sale
critic drug compani like consist success new drug growth
mode offset older drug declin sale due loss exclus competit new
improv treatment exampl type declin arthriti drug celebrex whose
sale peak around billion sinc fallen million patent
expir
next five year sever key patent expir occur hope off-set
growth newer drug patent expir includ lyrica sale
chantix/champix sale sutent sale ibranc sale
research develop effort continu off-set declin sale older drug
spend heavili research devlop keep new drug come pipelin
global drug market spend total billion billion
respect sale
march pipelin consist compound variou clinic trial phase
total phase final stage human clinic trial registr phase
fda approv final regulatori review drug market develop pipelin
includ potenti new treatment wide rang condit includ cancer obes arthriti heart
diseas diabet schizophrenia pain critic upcom pipelin event includ potenti fda approv
bavencio inlyta first-lin treatment renal cell carcinoma kidney cancer four potenti
biosimilar approv could repres billion opportun aggreg phase
readout rivipansel sickl cell diseas atop dermat addit phase
readout tanezumab osteoarthr chronic low back pain
market profil world-wide total prescript drug sale project grow compound annual
growth rate compound-annual-growth-rate period accord forecast evaluatepharma
key driver growth age develop popul especi babi
boomer age prime year health care need emerg market like see materi faster
growth prescript sale develop market howev due view
emerg market demand pharmaceut spur rise standard live global middl
class expand gain access advanc health care also develop market
govern increas health care spend
impact major develop june acquir billion
septemb acquir mediv mdvn billion curtail
acquisit activ total billion two-year period share repurchas
significantli increas billion billion
financi trend sale risen billion billion repres
three-year compound annual growth rate sale aid acquisit total
billion sinc start adjust pre-tax incom margin increas
primarili due reduct sg expens margin expens margin
adjust ep risen repres three-year compound-annual-growth-rate
improv profit margin help ep grow faster sale last three year also
note ep growth aid signific share buyback made net
repurchas billion worth share impact new stock issuanc reduc
share count process also paid billion dividend
cfo evp global
evp chief digit
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
slightli overvalu usd
neutral sinc juli technic indic
neutral
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
outlook sub-industri
next year neutral expect
modest revenu growth
driven slowdown novel drug approv
activ potenti new price regul
neg partial off-set
upcom favor period patent
expir also
expect gener maker continu struggl
grow earn lower cost foreign
competit continu prosper
banner year new brand
drug fda see slowdown
total novel drug approv
fda signific
surg versu combin approv
growth sub-industri
versu averag
new drug launch appear slow
howev fda approv
novel drug year june
period also observ
yoy declin spend
pharmaceut think
portend effort maintain margin sluggish
revenu growth year ahead
pharmaceut also face increas
risk potenti new drug price regul
juli presid indic
administr work new rule set
govern drug price use intern
index accord wall street journal
studi govern health system develop
countri like england norway canada often
pay less major brand
 center medicar medicaid
servic think intern
index rule would like drive higher price
foreign market lower one
would like still neg
overal impact sub-industri revenu
administr effort date lower drug
price regul
success intern index
signific risk weigh outlook
balanc neg factor face
brand drug maker expect
upcom favor period patent
expir typic biggest
revenu headwind base data
evaluatepharma annual global drug sale
risk expir patent averag
total forecast
drop fewer
patent cliff year ahead
posit brand drug sale
beyond brand firm make lion
share sub-industri market cap outlook
gener maker neg previous
anda would declin sever deflat
drove competitor industri
seem play
six-month move averag anda june
recent peak
longer think fewer competitor
enough stabil gener industri
howev india-bas gener maker
like take market share develop nation
firm due lower product cost --
india-bas produc oper
estim averag gross margin
versu top western
drop broader composit
year-to-d juli
pharmaceut
gain
base index
five-year market price perform jul
note sector sub-industri inform base
past perform indic futur perform
reli upon
compani
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
rais target ep estim
line peer-averag ep vs beat consensu
maintain ep estim deliv sale growth yoy
led strong growth sever blockbust drug includ prevnar
ibranc eliqui off-set greater competit elsewher
portfolio expect similar slow growth scenario due expect
loss exclus lyrica sale despit weak sale growth adjust
pre-tax incom yoy due materi improv margin cog
yoy produc save fund valuabl yoy
increas support higher margin think critic
improv growth new approv indic oncolog
sale area show materi promis view new treatment
breast lung cancer approv /colin scarola
keep target forward ep
estim brand peer gener peer ep
vs ahead view rais ep estim
aid lower share count repurchas share
lower tax rate juli
remain buy-back program sale fx benefit rose
innov essenti declin sale driven
solid sale growth eliqui ibranc xeljanz
partial off-set declin legaci product howev encourag
increas spend primarili relat advanc
late-stag develop program believ pipelin could produc
blockbust drug view aggress yet note
impact loss exclus product portfolio slow
significantli /jeffrey loo cfa
analyst research note compani news
pm et cfra keep hold opinion share pfizer inc
lower target ep estim --
histor forward price-to-earnings averag expect long-term organ
revenu growth improv narrow portfolio patent-protect drug
ep vs beat consensu maintain
ep estim total revenu fell yoy larg driven
off-pat drug segment upjohn revenu saw sale drop yoy
biopharma segment post solid growth yoy constant currenc
cc howev driven cc growth oncolog breast cancer drug
ibranc continu one strongest perform grow
sale yoy cc follow plan spin-out upjohn consum
segment expect fast-grow oncolog portfolio compris
total revenu today think improv long-term growth
remain neutral share see current price near fair
et cfra lower opinion share hold buy
keep target ep estim
unchang histor forward price-to-earnings averag due signific
litig risk competit lower-cost indian drug maker today
announc plan spin off-pat brand drug
busi upjohn asset yet unnam new compani
sharehold newco whose pro-forma free cash flow
around mean stake think well
deal better would earn
view given trail year downward trend
deal also increas resourc manag alleg price-fix litig risk
on-going market share loss india-bas competit view given
magnitud risk howev think long-term growth opportun
limit see share near fair valu adjust recommend
et cfra keep hold opinion share pfizer inc
keep target roughli line
histor peer averag ep estim ep vs
beat consensu maintain ep estim rais
sale growth yoy similar rate seen
full-year continu balanc strong growth newer drug
declin older one growth quarter led prevnar pneumococc
vaccin sale yoy ibranc breast cancer yoy
eliqui anti-clot yoy lipitor blood pressur
yoy xeljanz immunolog yoy strong demand drug
partial off-set lyrica neuropath pain yoy ahead
expect gener competit enbrel immunolog yoy
biosimilar competit think share perform averag
near term declin lyrica sale upon gener entri limit
pm et cfra keep hold opinion share pfizer inc
keep target peer-averag
ep estim ep vs beat consensu lower
ep estim initi sale
growth yoy similar rate seen first nine month
year led robust sale growth ibranc breast cancer sale
eliqui anti-clot sale xeljanz immunolog sale
three drug account sale
intern expans new indic expect three
continu robust growth year forecast overal sale fall
howev due lyrica neurosci sale like declin
precipit gener competit begin june view
long-term growth prospect favor howev due attract pipelin
promis phase trial on-going potenti three major
biosimilar approv /colin scarola
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
